Preparation of autologous leukemia and lymphoma vaccines expressing α-Gal epitopes

Journal of Hematotherapy and Stem Cell Research

Volumn 10, Issue 4, 2001, Pages 501-511

  Galili, U ^a   Chen, Z C ^a   Manches, O ^c   Plumas, J ^c   Preisler, H ^b  

^a RUSH MEDICAL COLLEGE   (United States)

^b RUSH CANCER INSTITUTE   (United States)

^c Etablissement de Tranfusion Sanguine   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GALACTOSYLTRANSFERASE; IMMUNOGLOBULIN G; SIALIDASE; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CELL MEMBRANE; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; IMMUNE SYSTEM; IMMUNOGENICITY; LEUKEMIA; LYMPH NODE; LYMPHOMA; METASTASIS; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; VACCINATION;

EID: 0034887224     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/15258160152509118     Document Type: Article

References (55)

1. Immunotherapy for cancer
2. Cancer vaccines
3. Antitumor T-lymphocyte response
4. Active specific immunotherapy in the treatment of patients with cancer
5. Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms
6. Pivotal role of the B7:CD28 pathway in transplantation, tolerance and tumor immunity
7. Costimulation of anti-tumor immunity by the B7 counter receptor for the T-lymphocyte molecule CD-28 and CTLA-4
8. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells
9. Mechanism of antigen uptake for presentation
10. Costimulation of T lymphocytes: The role of CD28, CDLA-4 and B7/BB1 in interleukin-2 production and immunotherapy
11. Dendritic cells as initiators of tumor immune response: A possible strategy for tumor immunotherapy
12. Primary of tumor-specific T cells in the draining lymph nodes after immunization with interleukin-2 secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination
13. Antigen localization regulates immune responses in a dose and time dependent fashion: A geographical view of immune reactivity
14. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
15. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
16. Bone-marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
17. Regession of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
18. Functional heterogeneity of human Fc receptors for immunoglobulin G
19. Type I (CD64) and Type II (CD32) Fc receptor-mediated phagocytosis by human blood dendritic cells
20. Human epidermal Langerhans cells express only trhe 40-kilodalton Fcγ receptor (FcRII)
21. Enhanced antigen presentation using human Fcγ receptor (monocyte/macrophage)-specific immunogens
22. Effect of antigen/antibody ratio on macrophage uptake, processing and presentation to T cells of antigen complexed with polyclonal antibodies
23. Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen
24. Enhanced antitoxin responses in irradiated mice elicited by complexes of tetanus toxoid and specific antibody
25. Inactivated Venezuelan equine encephalomyelitis virus vaccine complexed with specific antibody: Enhanced primary immune response and altered pattern of antibody class elicited
26. A unique natural human IgG antibody with anti-α-galactosyl specificity
27. Human natural anti-α-galactosyl IgG. II. The specific recognition of α(1-3)-linked galactose residues
28. The human natural anti-Gal IgG. III. The subtley of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies
29. One percent of circulating B lymphocytes are capable of producing the natural anti-Gal antibody
30. Evolutionary relationship between the anti-Gal antibody and the Galα1-3Gal epitope in primates
31. Man, apes, and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells
32. Evolution and pathophysiology of the human natural anti-Gal antibody
33. Gene sequences suggest inactivation of α1-3 galactosyltransferase in catarrhines after the divergence of apes from monkeys
34. Interaction between human natural anti-α-galactosyl immunoglobulin G and bacteria of the human flora
35. Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: A major obstacle for xenotransplantation in humans
36. Cardiac xenografts between primate species provide evidence for the importance of α-galactosyl determinant in hyperacute rejection
37. A novel mechanism of retrovirus inactivation in human serum mediated by α-galactosyl natural antibody
38. Sensitization of cells and retroviruses to human serum by α1-3galactosyltransferase
39. The natural anti-Gal antibody as a universal augmenter of autologous vaccine immunogenicity
40. Bovine α1-3galactosyltransferase: Isolation and characterization of a cDNA clone. Identification of homologous sequences in human genomic DNA
41. Isolation of a cDNA encoding murine UDP-galactose: α-D-galactosyl-1,4-N-acetyl-D-glucosamine α1,3 galactosyltransferase: Expression cloning by gene transfer
42. Defining the minimal size of catalytically active primate α1,3 galactosyltransferase: Structure function studies on the recombinant truncated enzyme
43. Synthesis of α-galactosyl epitopes by α1,3galactosyltransferase for opsonization of human tumor vaccines by antigalactose
44. Synthesis of α-gal epitopes of influenza virus vaccines by recombinant α1,3galactosyltransferase enables the formation of immune complexes with the natural anti-Gal antibody
45. Increased immunogenicity of tumor vaccines complexed with anti-Gal: Studies in knockout mice for alpha 1,3galactosyltransferase
46. Oocyte Galα1-3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse
47. Adult and neonatal anti-Gal response in knock-out mice for α1,3galactosyltransferase
48. Differential immune response to α-gal epitopes on xenografts and allografts: Implications for accommodation in xenotransplantation
49. Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by α1,3galactosyltransferase gene transfection
50. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes
51. A sensitive assay for measuring α-gal epitope expression on cells by a monoclonal anti-Gal antibody
52. Therapeutic effectiveness of neuraminidase treated tumor cells as an immunogen in man and experimental animals with leukemia
53. Specific immunotherapy with neuraminidase-modified leukemic cells: Experimental and clinical trials
54. Transplantation of fetal porcine pancreas to diabetic patients: Biochemical and histological evidence for graft survival
55. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters